These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 32011450)

  • 1. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
    Bylicki O; Guisier F; Monnet I; Doubre H; Gervais R; Janicot H; Perol M; Fournel P; Lamy R; Auliac JB; Chouaid C
    Medicine (Baltimore); 2020 Jan; 99(3):e18726. PubMed ID: 32011450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
    Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
    Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
    J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
    Bylicki O; Paleiron N; Margery J; Guisier F; Vergnenegre A; Robinet G; Auliac JB; Gervais R; Chouaid C
    Target Oncol; 2017 Oct; 12(5):563-569. PubMed ID: 28624922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
    Chalmers AW; Patel S; Boucher K; Cannon L; Esplin M; Luckart J; Graves N; Van Duren T; Akerley W
    Target Oncol; 2019 Aug; 14(4):417-421. PubMed ID: 31346927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
    Auliac JB; Monnet I; Dubos-Arvis C; Chiappa AM; Baize N; Bota S; Vergnenegre A; Doubre H; Locher C; Bizieux A; Robinet G; Chouaid C
    Target Oncol; 2017 Dec; 12(6):833-838. PubMed ID: 28762087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
    Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.
    Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB
    Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
    Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
    Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.